Treatment-resistant OCD: Pharmacotherapies in adults
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Serotonin reuptake inhibitor (SRI) medications are well established as first-line pharmacotherapeutic treatment for Obsessive-Compulsive Disorder (OCD). However, despite the excellent safety profile and demonstrated efficacy of these medications, a substantial proportion of individuals with OCD fail to attain sufficient benefit from SRIs. In this narrative review, we discuss clinical features of OCD that have been associated with poorer response to SRIs, and we present pharmacotherapeutic interventions that have been explored as augmenting or alternative treatments for treatment-resistant OCD. We additionally highlight non-SRI interventions for OCD that are currently under investigation. Pharmacotherapeutic interventions were identified via expert consensus. To assess the evidence base for individual pharmacotherapies, targeted searches for relevant English-language publications were performed on standard biomedical research databases, including MEDLINE. Information relevant to ongoing registered clinical trials in OCD was obtained by search of ClinicalTrials.gov. Pharmacotherapies are grouped for review in accordance with the general principles of Neuroscience-based Nomenclature (NbN). Clinical features of OCD that may suggest poorer response to SRI treatment include early age of onset, severity of illness, duration of untreated illness, and the presence of symmetry/ordering or hoarding-related symptoms. Based on evolving pathophysiologic models of OCD, diverse agents engaging serotonin, dopamine, norepinephrine, glutamate, and anti-inflammatory pathways have been explored as alternative or adjunctive therapies for treatment-resistant OCD and have at least preliminary evidence of efficacy. Medications with dopamine antagonist activity remain the most robustly evidence-based of augmenting interventions, yet dopamine antagonists benefit only a minority of those who try them and carry elevated risks of adverse effects. Interventions targeting glutamatergic and anti-inflammatory pathways are less well evidenced, but may offer more favorable benefit to risk profiles. Ongoing research should explore whether specific interventions may benefit individuals with particular features of treatment-resistant OCD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication
Ruscio, A. M., Stein, D. J., Chiu, W. T., & Kessler, R. C. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.94 · Cited by 2,771
Swedo, S. E., Leonard, H. L., Garvey, M., Mittleman, B., Allen, A. J., Perlmutter, S., Dow, S., Zamkoff, J., Dubbert, B. K., & Lougee, L. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.2.264 · Cited by 1,534
Baxter, L. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820090009002 · Cited by 1,293
Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice
Welch, J. M., Lu, J., Rodriguiz, R. M., Trotta, N. C., Peca, J., Ding, J.-D., Feliciano, C., Chen, M., Adams, J. P., Luo, J., et al. (2007) · Nature · doi:10.1038/nature06104 · Cited by 852
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789
Mataix-Cols, D., Rauch, S. L., Manzo, P. A., Jenike, M. A., & Baer, L. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1409 · Cited by 716
Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001823 · Cited by 635
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0080 · Cited by 576
Messaoudi, M., Violle, N., Bisson, J.-F., Desor, D., Javelot, H., & Rougeot, C. (2011) · Gut Microbes · doi:10.4161/gmic.2.4.16108 · Cited by 574
Pittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426
Pallanti, S., & Quercioli, L. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.028 · Cited by 408
Mataix‐Cols, D., de la Cruz, L. F., Nordsletten, A. E., Lenhard, F., Isomura, K., & Simpson, H. B. (2016) · World Psychiatry · doi:10.1002/wps.20299 · Cited by 386
Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386
ROSENBERG, D. R., MacMASTER, F. P., KESHAVAN, M. S., FITZGERALD, K. D., STEWART, C. M., & MOORE, G. J. (2000) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200009000-00008 · Cited by 377
Adults with early-onset obsessive-compulsive disorder
do Rosario-Campos, M. C., Leckman, J. F., Mercadante, M. T., Shavitt, R. G., Prado, H. D. S., Sada, P., Zamignani, D., & Miguel, E. C. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1899 · Cited by 373
Women Are at Greater Risk of OCD Than Men: A Meta-Analytic Review of OCD Prevalence Worldwide
Fawcett, E. J., Power, H., & Fawcett, J. M. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19r13085 · Cited by 344
Glutamatergic Dysfunction in OCD
Chakrabarty, K., Bhattacharyya, S., Christopher, R., & Khanna, S. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300733 · Cited by 344
Meta-analysis of the dose-response relationship of SSRI in obsessive–compulsive disorder
Bloch, M. H., McGuire, J., Landeros-Weisenberger, A., Leckman, J. F., & Pittenger, C. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.50 · Cited by 317
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.043 · Cited by 314
Marques, L., LeBlanc, N. J., Weingarden, H. M., Timpano, K. R., Jenike, M., & Wilhelm, S. (2010) · Depression and Anxiety · doi:10.1002/da.20694 · Cited by 283
Fontenelle, L. F., Oostermeijer, S., Harrison, B. J., Pantelis, C., & Yücel, M. (2011) · Drugs · doi:10.2165/11591790-000000000-00000 · Cited by 234
Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial
Nagele, P., Duma, A., Kopec, M., Gebara, M. A., Parsoei, A., Walker, M., Janski, A., Panagopoulos, V. N., Cristancho, P., Miller, J. P., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.016 · Cited by 230
Perani, D., Garibotto, V., Gorini, A., Moresco, R. M., Henin, M., Panzacchi, A., Matarrese, M., Carpinelli, A., Bellodi, L., & Fazio, F. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.04.233 · Cited by 219
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000740 · Cited by 211
Sapap3 and pathological grooming in humans: Results from the OCD collaborative genetics study
Bienvenu, O. J., Wang, Y., Shugart, Y. Y., Welch, J. M., Grados, M. A., Fyer, A. J., Rauch, S. L., McCracken, J. T., Rasmussen, S. A., Murphy, D. L., et al. (2009) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30897 · Cited by 207
Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder
Denys, D., van der Wee, N., Janssen, J., De Geus, F., & Westenberg, H. G. M. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.023 · Cited by 195
Zohar, J., Stahl, S., Moller, H.-J., Blier, P., Kupfer, D., Yamawaki, S., Uchida, H., Spedding, M., Goodwin, G. M., & Nutt, D. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.08.019 · Cited by 186
Anti-Brain Autoantibodies and Altered Excitatory Neurotransmitters in Obsessive–Compulsive Disorder
Bhattacharyya, S., Khanna, S., Chakrabarty, K., Mahadevan, A., Christopher, R., & Shankar, S. K. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.77 · Cited by 172
The erring brain: Error‐related negativity as an endophenotype for OCD—A review and meta‐analysis
Riesel, A. (2019) · Psychophysiology · doi:10.1111/psyp.13348 · Cited by 170
Veale, D., Miles, S., Smallcombe, N., Ghezai, H., Goldacre, B., & Hodsoll, J. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0317-5 · Cited by 162
Fineberg, N. A., Hollander, E., Pallanti, S., Walitza, S., Grünblatt, E., Dell’Osso, B. M., Albert, U., Geller, D. A., Brakoulias, V., Janardhan Reddy, Y. C., et al. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000314 · Cited by 161
A Single-Blinded Case-Control Study of Memantine in Severe Obsessive-Compulsive Disorder
Stewart, S. E., Jenike, E. A., Hezel, D. M., Stack, D. E., Dodman, N. H., Shuster, L., & Jenike, M. A. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181c856de · Cited by 158
Mataix-Cols, D., Frans, E., Pérez-Vigil, A., Kuja-Halkola, R., Gromark, C., Isomura, K., Fernández de la Cruz, L., Serlachius, E., Leckman, J. F., Crowley, J. J., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.215 · Cited by 153
Minocycline alters behavior, microglia and the gut microbiome in a trait-anxiety-dependent manner
Schmidtner, A. K., Slattery, D. A., Gläsner, J., Hiergeist, A., Gryksa, K., Malik, V. A., Hellmann-Regen, J., Heuser, I., Baghai, T. C., Gessner, A., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0556-9 · Cited by 153
Ghaleiha, A., Entezari, N., Modabbernia, A., Najand, B., Askari, N., Tabrizi, M., Ashrafi, M., Hajiaghaee, R., & Akhondzadeh, S. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.09.015 · Cited by 152
Quality of life in obsessive compulsive disorder
Macy, A. S., Theo, J. N., Kaufmann, S. C. V., Ghazzaoui, R. B., Pawlowski, P. A., Fakhry, H. I., Cassmassi, B. J., & IsHak, W. W. (2013) · CNS Spectrums · doi:10.1017/s1092852912000697 · Cited by 150
Dold, M., Aigner, M., Lanzenberger, R., & Kasper, S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv047 · Cited by 134
A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression
Nagele, P., Palanca, B. J., Gott, B., Brown, F., Barnes, L., Nguyen, T., Xiong, W., Salloum, N. C., Espejo, G. D., Lessov-Schlaggar, C. N., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe1376 · Cited by 133
Ahmari, S. E., & Dougherty, D. D. (2015) · Depression and Anxiety · doi:10.1002/da.22367 · Cited by 128
Abramovitch, A., Dar, R., Hermesh, H., & Schweiger, A. (2012) · Journal of Neuropsychology · doi:10.1111/j.1748-6653.2011.02021.x · Cited by 126
Role of dopamine in the pathophysiology and treatment of obsessive–compulsive disorder
Koo, M.-S., Kim, E.-J., Roh, D., & Kim, C.-H. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.148 · Cited by 125
Pharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond
Fineberg, N. A., Reghunandanan, S., Brown, A., & Pampaloni, I. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412461958 · Cited by 122
Hollander, E., Stein, D. J., Fineberg, N. A., Marteau, F., & Legault, M. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05911blu · Cited by 115
Fonseka, T. M., Richter, M. A., & Müller, D. J. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0510-8 · Cited by 93
D-Amphetamine in obsessive-compulsive disorder
Insel, T. R., Hamilton, J. A., Guttmacher, L. B., & Murphy, D. L. (1983) · Psychopharmacology · doi:10.1007/bf00436159 · Cited by 90
Pittenger, C., Bloch, M. H., Wasylink, S., Billingslea, E., Simpson, R., Jakubovski, E., Kelmendi, B., Sanacora, G., & Coric, V. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09123 · Cited by 80
Koran, L. M., Aboujaoude, E., & Gamel, N. N. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04605 · Cited by 79
Self-citationDo antipsychotics ameliorate or exacerbate Obsessive Compulsive Disorder symptoms?
Sareen, J., Kirshner, A., Lander, M., Kjernisted, K. D., Eleff, M. K., & Reiss, J. P. (2004) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.03.011 · Cited by 79
Rodriguez, C. I., Kegeles, L. S., Flood, P., & Simpson, H. B. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10l06653 · Cited by 59
How ecstasy and psilocybin are shaking up psychiatry
Tullis, P. (2021) · Nature · doi:10.1038/d41586-021-00187-9 · Cited by 58
Murray, G. K., Knolle, F., Ersche, K. D., Craig, K. J., Abbott, S., Shabbir, S. S., Fineberg, N. A., Suckling, J., Sahakian, B. J., Bullmore, E. T., et al. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05292-2 · Cited by 53
Heidari, M., Zarei, M., Hosseini, S. M. R., Taghvaei, R., Maleki, H., Tabrizi, M., Fallah, J., & Akhondzadeh, S. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000043 · Cited by 48
Acute Psychostimulant Challenge in Primary Obsessive-Compulsive Disorder
JOFFE, R. T., SWINSON, R. P., & LEVITT, A. J. (1991) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199108000-00003 · Cited by 46
Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder
Grassi, G., Cecchelli, C., Vignozzi, L., & Pacini, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s255375 · Cited by 44
Self-citationLiang, K., Wang, Y., Shugart, Y. Y., Grados, M., Fyer, A. J., Rauch, S., Murphy, D., McCracken, J., Rasmussen, S., Cullen, B., et al. (2008) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30713 · Cited by 42
Sharma, L. P., Thamby, A., Balachander, S., Janardhanan, C. N., Jaisoorya, T. S., Arumugham, S. S., & Reddy, Y. C. J. (2020) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2020.102183 · Cited by 34
Zheng, H., Jia, F., Han, H., Wang, S., Guo, G., Quan, D., Li, G., & Huang, H. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.12.010 · Cited by 28
Grant, J. E., Hook, R., Valle, S., Chesivoir, E., & Chamberlain, S. R. (2021) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000368 · Cited by 24
Naftalovich, H., Tauber, N., & Kalanthroff, E. (2020) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2020.102316 · Cited by 14
Andrade, C. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14f09704 · Cited by 14
Cited by
A closer look to neural pathways and psychopharmacology of obsessive compulsive disorder
Gargano, S. P., Santos, M. G., Taylor, S. M., & Pastis, I. (2023) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2023.1282246 · Cited by 18
“In the US and Canada, mirtazapine is also recommended as a second-line alternative medication (Koran et al., 2005; van Roessel et al., 2023).”
BackgroundObsessive-compulsive disorder – A state-of-the-art review
Endres, D., Schiele, M. A., von Zedtwitz, K., Dressle, R. J., Maier, A., Hohagen, F., Baldermann, J. C., Coenen, V. A., Jelinek, L., Domschke, K., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106320 · Cited by 11
Obukhov, N. V. (2024) · International Journal of Clinical and Experimental Hypnosis · doi:10.1080/00207144.2024.2391358 · Cited by 3
Metadata
- Authors
- van Roessel, P. J., Grassi, G., Aboujaoude, E. N., Menchón, J. M., Van Ameringen, M., & Rodríguez, C. I.
- Venue
- Comprehensive Psychiatry
- Publisher
- Elsevier BV
- Published
- 2023-01
- Volume
- 120
- Pages
- 152352
- ISSN
- 0010-440X (ISSN-L)
- OpenAlex
- W4307235791
- Cited by
- 86
- References
- 63
- FWCI
- 14.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.